

Vaccinex enters into a research collaboration with Janssen R&D for the creation of novel anti-cancer agents

December 2, 2014 4:43 PM ET

12/2/2014

ROCHESTER, NY – Vaccinex , Inc. announced today that it has entered into a research collaboration with Janssen Research & Development, LLC, a Pharmaceutical Company of Johnson & Johnson, for the creation of novel anti-cancer agents. The terms of the collaboration were not disclosed. Based in Rochester, New York, Vaccinex is a privately held clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies to treat cancer and neurodegenerative diseases, including multiple sclerosis and Huntington's disease. The company utilizes its proprietary ActivMAb® Antibody Discovery Technology for rapid, mammalian cell-based antibody selection to build its antibody pipeline and in service to its biopharmaceutical partners. www.vaccinex.com.